<DOC>
	<DOCNO>NCT00998218</DOCNO>
	<brief_summary>The purpose investigation thoroughly investigate effect ranolazine arrhythmias microvolt t-wave alternans patient automatic implantable cardioverter defibrillator ( AICD ) implant either prophylactically prevent sudden cardiac death , well patient may clinically significant arrhythmic event prompt insertion automatic implantable cardioverter defibrillator . It anticipate study provide valuable new insight potential use ranolazine treat arrhythmia high risk patient .</brief_summary>
	<brief_title>Effect Ranolazine Arrhythmias Microvolt T- Wave Alternans ( MVTWA ) Patients With LV Dysfunction</brief_title>
	<detailed_description>The device clinic Aspirus Wausau Hospital follow approximately 2800 patient pacemaker automatic implantable cardioverter defibrillator ( AICD ) . Approximately 300 patient AICD insert primary secondary arrhythmia prevention . From 300 patient , approximately 20 patient AICD implant either prophylactically establish malignant arrhythmia recruit short study . This study investigate effect ranolazine arrhythmia detect device see reduce abnormal beat . It also study whether ranolazine impact microvolt t-wave alternans ( MVTWA ) , measure tendency serious arrhythmia . Approximately 10 patient ischemic cardiomyopathy 10 patient non-ischemic cardiomyopathy chosen . All ejection fraction 40 % less . Prior institution ranolazine , MVTWA study perform ( Cambridge Heart Inc.Â® ) . The AICD use generate increase heart rate need induce MVTWA . Each patient MVTWA assess 80 beats/minute 110 beats/minute . To eliminate interpretation bias , auto interpretation feature MVTWA device use determine whether study positive ( MVTWA present ) negative ( MVTWA absent ) indeterminate . In coarse study , patient undergo total 3 MVTWA study identical manner use AICD provide need change heart rate . After informed consent obtain patient begin 10-day `` ranolazine run '' . Each randomized participant give 10-day supply ranolazine make certain tolerate medication ( constipation far common limit side effect ) . Each participant start 500 mg BID 3 day increase 1000 mg BID . Participants able tolerate least 500 mg BID consider eligible participate study randomly assign either ranolazine 1000 mg BID ( 500 mg BID 1000 mg dose tolerate ) comparable placebo next 4 week . At least 3 day run prior randomization , patient bring baseline MVTWA device clinic purge AICD data reset data counter . The patient immediately begin either placebo ranolazine accord randomization . After 4 week , MVTWA study repeat either placebo ranolazine arrhythmia data load AICD , record arrhythmia counter device operation counter reset . Each patient cross therapy ( ranolazine placebo ) next 4 week device interrogate MVTWA study repeat identical manner .</detailed_description>
	<mesh_term>Death</mesh_term>
	<mesh_term>Death , Sudden , Cardiac</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Implant AICD prevention sudden cardiac death Implant AICD prevention sudden cardiac death Any antiarrhythmic agent ( betablockers ) History intolerance ranolazine run . History severe constipation define require laxative 5 time week order bowel movement . Because weak inhibitory effect ranolazine cytochrome p450 , CYP 3A4 , certain drug metabolize system could accumulate . Although clinically significant interaction ranolazine agent demonstrate , patient maximum dos simvastatin , patient verapamil diltiazem exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Sudden Cardiac Death</keyword>
	<keyword>Arrythmias</keyword>
	<keyword>Triggered activity</keyword>
	<keyword>leave ventricular dysfunction</keyword>
</DOC>